Intangible Assets (Narrative) (Details) - USD ($) |
12 Months Ended | |||
|---|---|---|---|---|
Aug. 14, 2022 |
Jun. 30, 2023 |
Jun. 30, 2022 |
Aug. 23, 2021 |
|
| Finite-Lived Intangible Assets [Line Items] | ||||
| Impairment of intangible assets | $ 565,000 | |||
| Amortization of Intangible Assets | 126,000 | $ 401,000 | ||
| Patents and Licenses [Member] | ||||
| Finite-Lived Intangible Assets [Line Items] | ||||
| Impairment of intangible assets | $ 25,000 | 565,000 | $ 0 | |
| Amortization of Intangible Assets | $ 47,000 | |||
| Weighted average remaining life | 1 year 6 months | |||
| Intellectual Property [Member] | ||||
| Finite-Lived Intangible Assets [Line Items] | ||||
| Amortization of Intangible Assets | $ 79,000 | |||
| Weighted average remaining life | 19 years 3 months 18 days | |||
| RubrYc Therapeutics, Inc. [Member] | Immune-Oncology Antibodies (RTX-003) [Member] | ||||
| Finite-Lived Intangible Assets [Line Items] | ||||
| Investment | $ 7,500,000 | |||
| X | ||||||||||
- Definition The amount of investment under the stock purchase agreement. No definition available.
|
| X | ||||||||||
- Definition The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|